-
NASDAQ Stocks Hitting 52-Week Highs
Tuesday, June 14, 2011 - 10:21am | 135Ulta Salon, Cosmetics & Fragrance Inc (NASDAQ: ULTA) shares rose 1.56% to create a new 52-week high of $58.65. ULTA's trailing-twelve-month ROE is 21.23%. Oncothyreon Inc (NASDAQ: ONTY) shares gained 5.36% to create a new 52-week high of $7.47. ONTY shares have jumped 91.62% over the past 52...
-
J.P. Morgan Comments On Vertex Collaboration
Tuesday, June 14, 2011 - 8:58am | 111According to J.P. Morgan, Vertex Pharmaceuticals (NASDAQ: VRTX) announced a WW collaboration with Alios Biopharma that would bolster its HCV pipeline by the addition of two nucleotide polymerase drugs (“nucs”; ALS-2200 and ALS-2158). J.P. Morgan said that these assets are very early stage (in...
-
Rosetta Genomics Signs Marketing Agreement With PACE Claims Services for miRview meso
Tuesday, June 14, 2011 - 8:32am | 184Rosetta Genomics (NASDAQ: ROSG) announces the signing of an exclusive marketing agreement with PACE Claims Services LLC to provide educational and marketing services on behalf of Rosetta Genomics' miRview meso diagnostic test to defendants and insurers in mesothelioma legal cases worldwide. PACE...
-
Benzinga's Top Pre-Market Losers
Tuesday, June 14, 2011 - 8:26am | 136SIGA Technologies Inc (NASDAQ: SIGA) dipped 9.01% to $11.01 in the pre-market session. SIGA's PEG ratio is 35.91. ProShares UltraPro Short QQQ (NASDAQ: SQQQ) dropped 2.15% to $28.20 in the pre-market trading. Ness Technologies Inc (NASDAQ: NSTC) moved down 0.33% to $7.57 in the pre-market...
-
Bank of America Reiterates $116 PO on Biogen
Tuesday, June 14, 2011 - 7:59am | 134Bank of America is reiterating its $116 price objective on shares of Biogen (NASDAQ: BIIB). “Our report today outlines analyses that support a strong competitive profile for BIIB's late stage oral multiple sclerosis drug candidate BG-12, and we reiterate our $116 PO ahead of key data catalysts...
-
J.P. Morgan Recaps Amylin Pharmaceuticals Data
Tuesday, June 14, 2011 - 7:58am | 92J.P. Morgan is recapping script data from Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). “In this note, we recap key script data in the diabetes drug landscape with a focus on the GLP-1 market,” J.P. Morgan writes. “Specifically for the week ended June 3, Byetta TRx was low and NRx was in line with...
-
Cell Therapeutics Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
Tuesday, June 14, 2011 - 6:56am | 323Cell Therapeutics (NASDAQ: CTIC) today announced that it met with the U.S. Food and Drug Administration's Division of Oncology Drug Products. The meeting provided a pathway for re-submitting CTI's New Drug Application for pixantrone for relapsed or refractory aggressive non-Hodgkin's lymphoma...
-
Stocks to Watch for 6/14/11: Fresh 52-Week Highs and Lows
Tuesday, June 14, 2011 - 4:15am | 2234The following stocks hit new 52-week highs in Monday's trading session: 1) Greif (NYSE: GEF): Shares of Greif hit a 52-week high of $67.36 in Monday's trading session. The stock closed at $67.04. The year-to-date performance of Greif has been a gain of 9%. 2) Raptor Pharmaceutical (NASDAQ: RPTP...
-
Health Care Sector Showing Strength
Monday, June 13, 2011 - 1:28pm | 382The Health Care Sector is the strongest area of the market in today's trading session, currently up 0.5% on the day. The best performing stocks in the S&P 500 Health Care Sector currently are: 1) Forest Laboratories (NYSE: FRX): Shares of Forest Laboratories are currently trading up 1.8% from...
-
Puts Purchased on Synta Pharmaceuticals
Monday, June 13, 2011 - 1:21pm | 121Shares of Synta Pharmaceuticals (NASDAQ: SNTA) are lower on the session by 3.65%, currently trading at $4.75. The stock has been moving largely lower over the past four weeks and is currently trading below the 50-day and 200-day moving averages. Options traders are buying puts on the name today....
-
CytRx Reports Positive Preliminary Results from ENABLE Phase 2 Clinical Trial with Bafetinib in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia
Monday, June 13, 2011 - 10:00am | 93CytRx Corporation (Nasdaq: CYTR) today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic...
-
CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in Hungary
Monday, June 13, 2011 - 9:42am | 102CEL-SCI Corporation (NYSE: CVM) announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at...
-
Rodman & Renshaw Reiterate Market Outperform and PT of $7 on BioCryst Pharmaceuticals
Monday, June 13, 2011 - 9:38am | 151Rodman & Renshaw reiterates its Market Outperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX). At the same time, Rodman & Renshaw left its price target unchanged at $7. In a research report published today, Rodman & Renshaw states, "We are reiterating our Market Outperform /...
-
Amazon.com (AMZN), Pharmasset (VRUS) Look Set for More Downside
Monday, June 13, 2011 - 9:00am | 298Amazon.com, Inc. (AMZN) – spent all of last week consolidating beneath its key moving averages which forecast another move lower. We can anticipate a move down to prior minor support at 175 and than potentially to major support at 160 over time. Best entry would be at or near 189 with tight stops...
-
Piper Jaffray Reiterates Overweight Rating On Seattle Genetics
Monday, June 13, 2011 - 8:35am | 102According to Piper Jaffray, Seattle Genetics (NASDAQ: SGEN) Overweight rating is reiterated. Piper Jaffray said that at the European Hematology Association (EHA) meeting in London over the weekend, SGEN reported updated data on ADCETRIS. “The only ODAC panel on the calendar for this summer to...